Phase 1 study of TRU-015, a CD20-directed small modular immunopharmaceutical (SMIP™) protein therapeutic, in subjects with rheumatoid arthritis

Detalles Bibliográficos
Autores principales: Burge, DJ, Bookbinder, SA, Kivitz, AJ, Fleischmann, RM, Shu, C, Bannink, J, Barone, D
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2007
Materias:
Poster Presentation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4061957/
http://dx.doi.org/10.1186/ar2257
_version_ 1782321580249972736
author Burge, DJ
Bookbinder, SA
Kivitz, AJ
Fleischmann, RM
Shu, C
Bannink, J
Barone, D
author_facet Burge, DJ
Bookbinder, SA
Kivitz, AJ
Fleischmann, RM
Shu, C
Bannink, J
Barone, D
author_sort Burge, DJ
collection PubMed
description
format Online
Article
Text
id pubmed-4061957
institution National Center for Biotechnology Information
language English
publishDate 2007
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-40619572014-06-19 Phase 1 study of TRU-015, a CD20-directed small modular immunopharmaceutical (SMIP™) protein therapeutic, in subjects with rheumatoid arthritis Burge, DJ Bookbinder, SA Kivitz, AJ Fleischmann, RM Shu, C Bannink, J Barone, D Arthritis Res Ther Poster Presentation BioMed Central 2007 2007-10-19 /pmc/articles/PMC4061957/ http://dx.doi.org/10.1186/ar2257 Text en Copyright © 2007 BioMed Central Ltd
spellingShingle Poster Presentation
Burge, DJ
Bookbinder, SA
Kivitz, AJ
Fleischmann, RM
Shu, C
Bannink, J
Barone, D
Phase 1 study of TRU-015, a CD20-directed small modular immunopharmaceutical (SMIP™) protein therapeutic, in subjects with rheumatoid arthritis
title Phase 1 study of TRU-015, a CD20-directed small modular immunopharmaceutical (SMIP™) protein therapeutic, in subjects with rheumatoid arthritis
title_full Phase 1 study of TRU-015, a CD20-directed small modular immunopharmaceutical (SMIP™) protein therapeutic, in subjects with rheumatoid arthritis
title_fullStr Phase 1 study of TRU-015, a CD20-directed small modular immunopharmaceutical (SMIP™) protein therapeutic, in subjects with rheumatoid arthritis
title_full_unstemmed Phase 1 study of TRU-015, a CD20-directed small modular immunopharmaceutical (SMIP™) protein therapeutic, in subjects with rheumatoid arthritis
title_short Phase 1 study of TRU-015, a CD20-directed small modular immunopharmaceutical (SMIP™) protein therapeutic, in subjects with rheumatoid arthritis
title_sort phase 1 study of tru-015, a cd20-directed small modular immunopharmaceutical (smip™) protein therapeutic, in subjects with rheumatoid arthritis
topic Poster Presentation
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4061957/
http://dx.doi.org/10.1186/ar2257
work_keys_str_mv AT burgedj phase1studyoftru015acd20directedsmallmodularimmunopharmaceuticalsmipproteintherapeuticinsubjectswithrheumatoidarthritis
AT bookbindersa phase1studyoftru015acd20directedsmallmodularimmunopharmaceuticalsmipproteintherapeuticinsubjectswithrheumatoidarthritis
AT kivitzaj phase1studyoftru015acd20directedsmallmodularimmunopharmaceuticalsmipproteintherapeuticinsubjectswithrheumatoidarthritis
AT fleischmannrm phase1studyoftru015acd20directedsmallmodularimmunopharmaceuticalsmipproteintherapeuticinsubjectswithrheumatoidarthritis
AT shuc phase1studyoftru015acd20directedsmallmodularimmunopharmaceuticalsmipproteintherapeuticinsubjectswithrheumatoidarthritis
AT banninkj phase1studyoftru015acd20directedsmallmodularimmunopharmaceuticalsmipproteintherapeuticinsubjectswithrheumatoidarthritis
AT baroned phase1studyoftru015acd20directedsmallmodularimmunopharmaceuticalsmipproteintherapeuticinsubjectswithrheumatoidarthritis

Ejemplares similares